Targeting autoimmune pulmonary alveolar proteinosis with GM-CSF: insights from clinical trials and emerging therapies.
GM-CSF-targeted therapies offer durable improvement for patients with a rare lung disease, potentially reducing need for repeated lung procedures.
GM-CSF-targeted therapies (inhaled molgramostim and IV sargramostim) show durable clinical benefit in autoimmune pulmonary alveolar proteinosis (aPAP) based on clinical trial data. Emerging approaches including rituximab and gene therapy may complement or replace whole-lung lavage in future treatment paradigms.
What the study was
- Study design
- narrative_review
- Category
- rare_diseases
- Maturity
- Validated
Why it surfaced
Comprehensive review of emerging therapies for a rare autoimmune lung disease with high unmet need. Relevant to rare diseases watchlist. Expert Opinion in Biological Therapy is the leading journal in this space; authors from centers with aPAP expertise.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.